NASDAQ:ERNA Eterna Therapeutics (ERNA) Stock Price, News & Analysis $0.22 +0.01 (+5.42%) Closing price 04/25/2025 03:59 PM EasternExtended Trading$0.21 -0.01 (-3.70%) As of 04/25/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Eterna Therapeutics Stock (NASDAQ:ERNA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Eterna Therapeutics alerts:Sign Up Key Stats Today's Range$0.19▼$0.2250-Day Range$0.17▼$0.3552-Week Range$0.15▼$2.63Volume210,780 shsAverage Volume2.79 million shsMarket Capitalization$11.28 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewEterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Read More… Eterna Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks30th Percentile Overall ScoreERNA MarketRank™: Eterna Therapeutics scored higher than 30% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Eterna Therapeutics. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Eterna Therapeutics is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eterna Therapeutics is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEterna Therapeutics has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Eterna Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.90% of the float of Eterna Therapeutics has been sold short.Short Interest Ratio / Days to CoverEterna Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Eterna Therapeutics has recently decreased by 19.53%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEterna Therapeutics does not currently pay a dividend.Dividend GrowthEterna Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.90% of the float of Eterna Therapeutics has been sold short.Short Interest Ratio / Days to CoverEterna Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Eterna Therapeutics has recently decreased by 19.53%, indicating that investor sentiment is improving significantly. News and Social Media2.7 / 5News Sentiment0.94 News SentimentEterna Therapeutics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Eterna Therapeutics this week, compared to 0 articles on an average week.Search Interest2 people have searched for ERNA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Eterna Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.49% of the stock of Eterna Therapeutics is held by insiders.Percentage Held by Institutions70.55% of the stock of Eterna Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Eterna Therapeutics' insider trading history. Receive ERNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eterna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ERNA Stock News HeadlinesErnexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025April 22, 2025 | globenewswire.comErnexa Therapeutics files to sell 10.44M shares of common stock for holdersApril 17, 2025 | markets.businessinsider.comHere’s How to Claim Your Stake in Elon’s Private Company, xAIElon Musk has done it again. He’s developed a powerful new AI model that’s already turning heads — and turning the industry upside down. Some say it could threaten Google’s search engine dominance. Others believe it could mark the beginning of the end for ChatGPT.April 26, 2025 | Brownstone Research (Ad)Contrasting Annovis Bio (NYSE:ANVS) and Eterna Therapeutics (NASDAQ:ERNA)April 17, 2025 | americanbankingnews.comErnexa Therapeutics Closes New Funding RoundApril 3, 2025 | globenewswire.comEterna changes name to Ernexa TherapeuticsMarch 27, 2025 | markets.businessinsider.comEterna Therapeutics Changes Name to Ernexa Therapeutics to Reflect New Strategic Focus on Ovarian Cancer and Autoimmune DiseaseMarch 25, 2025 | markets.businessinsider.comEterna hosts inaugural meeting of newly formed SABFebruary 26, 2025 | markets.businessinsider.comSee More Headlines ERNA Stock Analysis - Frequently Asked Questions How have ERNA shares performed this year? Eterna Therapeutics' stock was trading at $0.2940 at the start of the year. Since then, ERNA stock has decreased by 26.5% and is now trading at $0.2160. View the best growth stocks for 2025 here. How were Eterna Therapeutics' earnings last quarter? Eterna Therapeutics Inc. (NASDAQ:ERNA) released its quarterly earnings results on Tuesday, November, 12th. The company reported ($4.92) EPS for the quarter. The company earned $0.49 million during the quarter. How do I buy shares of Eterna Therapeutics? Shares of ERNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Eterna Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eterna Therapeutics investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), NIO (NIO), Bakkt (BKKT) and Inuvo (INUV). Company Calendar Last Earnings11/12/2024Today4/26/2025Next Earnings (Estimated)5/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ERNA CIK748592 Webwww.brooklynitx.com Phone(212) 582-1199Fax760-438-3505Employees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($8.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,670,000.00 Net Margins-7,513.88% Pretax Margin-7,511.37% Return on EquityN/A Return on Assets-117.48% Debt Debt-to-Equity RatioN/A Current Ratio0.48 Quick Ratio0.48 Sales & Book Value Annual Sales$582,000.00 Price / Sales19.39 Cash FlowN/A Price / Cash FlowN/A Book Value$0.41 per share Price / Book0.53Miscellaneous Outstanding Shares52,245,000Free Float5,168,000Market Cap$11.28 million OptionableNo Data Beta4.79 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free Report This page (NASDAQ:ERNA) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredIt’s absolute chaos in Silicon Valley right now…If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eterna Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eterna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.